DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 50 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,099 | -2.6% | 165,016 | +7.9% | 0.02% | +50.0% |
| Q2 2023 | $2,154 | +734.9% | 152,974 | +815.1% | 0.02% | +433.3% |
| Q1 2023 | $258 | +65.4% | 16,717 | +75.6% | 0.00% | +50.0% |
| Q4 2022 | $156 | -100.0% | 9,520 | -54.3% | 0.00% | -60.0% |
| Q3 2022 | $385,000 | -29.6% | 20,836 | -49.9% | 0.01% | -16.7% |
| Q2 2022 | $547,000 | +88.0% | 41,583 | +386.2% | 0.01% | +500.0% |
| Q3 2021 | $291,000 | -18.5% | 8,552 | -12.4% | 0.00% | -50.0% |
| Q2 2021 | $357,000 | -44.3% | 9,759 | -31.8% | 0.00% | -33.3% |
| Q1 2021 | $641,000 | +181.1% | 14,299 | +257.7% | 0.00% | +200.0% |
| Q4 2020 | $228,000 | -91.2% | 3,998 | -92.1% | 0.00% | -93.8% |
| Q3 2020 | $2,584,000 | +1420.0% | 50,368 | +1668.5% | 0.02% | +1500.0% |
| Q2 2020 | $170,000 | -5.6% | 2,848 | -34.7% | 0.00% | -50.0% |
| Q1 2020 | $180,000 | -2.7% | 4,360 | +46.6% | 0.00% | 0.0% |
| Q4 2019 | $185,000 | -44.6% | 2,975 | -65.0% | 0.00% | -33.3% |
| Q2 2018 | $334,000 | +119.7% | 8,495 | +12.1% | 0.00% | +200.0% |
| Q1 2018 | $152,000 | +6.3% | 7,576 | +0.4% | 0.00% | 0.0% |
| Q3 2017 | $143,000 | – | 7,544 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
| SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
| PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
| Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
| EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
| Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
| VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |